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Table 2
Transplant Outcomes for MMUD vs MUD Grafts
Outcome Group N 1-yr CI 2-yr CI p-
value
MUD 169 0.72 (0.64-0.79) 0.60 (0.51-0.67) -
8/10 Loci 31 0.57 (0.38-0.73) 0.43 (0.25-0.60) 0.04
OS 9/10 Loci 105 0.71 (0.61-0.79) 0.56 (0.45-0.65)
Single DQB1 18 0.78 (0.51-0.91) 0.72 (0.45-0.87) 0.44
Single C 26 0.68 (0.46-0.83) 0.45 (0.25-0.64) 0.07
Single class 1
or DRB1
87 0.70 (0.59-0.79) 0.522 (0.41-0.63) 0.17
MUD 169 0.65 (0.57-0.72) 0.54 (0.45-0.62) -
8/10 Loci 31 0.47 (0.29-0.64) 0.40 (0.23-0.57) 0.04
DFS 9/10 Loci 105 0.65 (0.55-0.74) 0.50 (0.40-0.60)
Single DQB 18 0.78 (0.51-0.91) 0.72 (0 45-0.87) 0.29
Single C 26 0.56 (0.35-0.73) 0.37 (0.18-0.56) 0.14
Single DQB1 87 0.64 (0.53-0.73) 0.47 (0.36-0.58) 0.42
MUD 169 0.09 (0.04-0.14) 0.13 (0.08-0.19) -
8/10 Loci 31 0.07 (0.01-0.19) 0.13 (0.40-0.28) 0.36
aGvHD
(Gr 2-4)
9/10 Loci 105 0.14 (0.08-0.22) 0.21 (0.14-0.30)
Single DQB1 18 0.17 (0.04-0.37) 0.17 (0.04-0.37) 0.21
Single C 26 0 04 (0.00-0.17) 0.23 (0.09-0.41) 0.62
Single class 1
or DRB1
87 0.14 (0.08-0.22) 0.22 (0.14-0.32) 0.21
MUD 169 0.05 (0.02-0.09) 0.10 (0.05-0.16) -
8/10 Loci 31 0.03 (0.00-0.15) 0.03 (0.00-0.15) 0.14
cGvHD 9/10 Loci 105 0.03 (0.01-0.08) 0.03 (0.01-0.08)
Single DQB1 18 0.06 (0.00-0.25) 0.06 (0.00-0.25) 0.67
Single C 26 0.05 (0.00-0.20) 0.05 (0.00-0.20) 0.41
Single class 1
or DRB1
87 0.03 (0.00-0.08) 0.03 (0.00-0.08) 0.06
*As appropriate, logrank or Gray’s test p-value comparing outcomes for
single DQB1, Single C and Single class 1 or DRB1 to MUD transplants.
Similarly, outcomes were compared across 8/10 loci, 9/10 loci and 10/10 loci
MUD transplants.
Abstracts / Biol Blood Marrow Transplant 20 (2014) S128eS150S144& sheep RBC rosetting (sRBCr) and for PB by automated
CD34+ selection +/- sRBCr. Conditioning regimens were
ablative and all included ATG. Patients were in remission or
had a low volume of disease. No pharmacologic GvHD pro-
phylaxis was given. For different levels of mismatch, overall
(OS) and disease-free survival (DFS) were compared using
Kaplan-Meier curves and the logrank test. Cumulative inci-
dence functions and Gray’s test compared the incidence of
grade 2-4 aGvHD and cGvHD. Results were compared with
169 TCD HLA matched unrelated donor (MUD) grafts during
the same period.
Results: Table 1 lists demographics. Several subgroups had
limited numbers of patients. Table 2 shows cumulative
incidence (CI) for outcomes, and Figure 1 survival curves to 5
yrs. There was no difference in outcomes for 1 loci MMUD vs.
MUD grafts. There was no statistical difference in outcomes
for a single C vs. any single non C mismatch. Nearly all acute
GVHDwas 2-3, and therewere only 4 limited chronic GVHDs.
OS and DFS were lower for >1 loci MMUD transplants.
Conclusion: These results support the use of TCD MMUD
grafts as alternatives for patients lacking a MUD or ineligible
for a CB graft.198
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Aims:We reported the impact of hemophagocytic syndrome
(HPS) on engraftment failure in cord blood transplantation
(CBT). The aim of this study was to explore pathogenesis
underlying HPS.
Methods: We retrospectively reviewed 351 patients who
underwent single CBT using ﬂudarabine-based regimens
at our institute from January 2002 to July 2011
consecutively.
Results: Median age was 58 years (range, 17-82).Diagnoses
were AML/MDS (n¼209), ALL/ML (n¼103), and others
(n¼36). Tacrolimus plus MMF (TAC+MMF) were used in 196
cases as GVHD prophylaxis, while TAC alone in 155. HPS
developed in 33 patients at a median of 19 days post-CBT.
The cumulative incidence of HPS was 9.4%. Development of
HPS had a negative impact signiﬁcantly on neutrophil
engraftment (33.3% with HPS vs 83.3% without HPS,
p¼<0.01), which resulted in inferior overall survival rate.
Majority of the HPS patients (25/30) showed donor-domi-
nant chimerism at the diagnosis of HPS. Patients with severe
form of pre-engraftment immune reactions (sPIR) showed
signiﬁcantly higher incidence of HPS than those without PIR
(51.9% vs 6.6% p¼<0.01). Patients who received cord blood
unit with higher degree of HLA antigen mismatch in GVH
direction (2 vs 0-1) also showed higher incidence of HPS
(11.5% vs 4.8% p¼<0.04). TAC+MMF decreased the incidence
of sPIR and HPS compared to TAC alone (2.8% vs 15.3%
p¼<0.01 and 4.6% vs 15.5% p¼ <0.01, respectively), which
had a trend toward higher engraftment rate (83.7% vs 72.3%
p¼0.07). In multivariate analysis, GVHD prophylaxis using
TAC alone, lower number of CD34+ cells infused (>0.8x105/kg
vs <0.8x105/kg) and higher degree of HLA antigen mismatch
in GVH direction were signiﬁcantly associated with HPS
development.
Conclusion: HPS was closely associated with engraftment
failure in our CBT cohort. sPIR plays an crucial role of
developing HPS and was possibly controlled by intensiﬁca-
tion of GVHD prophylaxis.IMMUNE RECONSTITUTION
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We previously published data from a group of 32 heavily
treated adult cord blood transplant (CBT) recipients and
